

## Index

### **a**

- Addison's disease 166
- adipose tissue 15
- advanced glycation end (AGE)
  - products 9, 99
  - in human lens
    - in chronological order 192–193
    - glucose vs. ascorbic acid 193–195
    - significance of 196–197
    - structure 192–193
  - pentosidine 9
- age-altered LLP 25, 168
- aged, long-lived proteins 162
- AGE products *see* advanced glycation end (AGE) products
- age-related cataract 65–71, 128–129, 189
- age-related disorders, LLPs
  - abundant macromolecules 26
  - autoimmune diseases 25
  - collagen 26–27
  - cytosol/nuclear communication 25–26
  - elastin 26
  - nuclear transcription 26
- age-related lens crystallin
  - modifications 71, 191
- age-related macular degeneration (AMD) 14
- age-related nuclear cataract (ARNC) 12–13, 23, 106–108, 128, 149, 189
- aging 18, 98
  - adipose tissue 15
  - brain 16, 109
  - cellular proteostasis alteration 113
  - circulatory system 112
  - decreased protein turnover 114
  - digestive system 112–113
  - effect of 183
  - feature of 97
  - heart 17
  - isomerization and epimerization 180
  - joints 19
  - kidney 15
  - Kohn definition of 189
  - liver 20
  - LLPs 6
  - in long-lived animals 2
  - lung 18
  - lysosome function and proteostasis
    - connection 183
  - oocytes 14–15
  - pancreas 19, 20
  - protein changes and DNA changes 21–22
  - protein crosslinking 101, 102
  - pulmonary system 112
  - respiratory system 112
  - retina 13–14
  - of species 1
  - vitreous humor 13, 108
- alanine 7
- Alzheimer disease (AD) 16, 27, 74, 109
- amine catalyzed ascorbic acid
  - degradation 191
- D-amino acids 8, 12, 111, 112, 147, 161
- amorphous aggregates 72, 74–76, 133

- amyloid fibrils  
 aggregates 72  
 polymorphism in 74  
 structure of 73–74  
 in vitro formation 76
- amyloid- $\beta$  ( $A\beta$ ) fibril structure 73
- amyotrophic lateral sclerosis  
 (ALS) 27, 110–111
- animal models 16, 28–29, 131
- anti-citrullinated protein antibodies 167
- antigen retrieval 44
- antiphospholipid antibody syndrome 167
- aquaporin-0 (AQP0) 49–51
- aquaporin 1 (AQP1) 132
- articular cartilage matrix 112
- ascorbic acid, in human lens  
 degradation products 191  
 chemical pathways of  
 degradation 191–192  
 vs. glucose, as source of AGEs 193  
 homeostasis 190  
 lenticular concentrations 190  
 as source of age-related damage 190–191  
 as source of oxoaldehydes 195
- ascorbylation, lens and brain 196–197
- Asn deamidation 29, 101, 106, 108, 178–179
- D-Asp 8, 9, 10, 18, 19, 100, 101, 109, 112,  
 132, 133, 146, 162, 179
- Asp isomerization 178–179
- ATP-dependent molecular chaperones 73
- autoimmune diseases 25, 159, 165, 168  
 genetic risk factors associated with 169  
 LLPs (*see* long-lived proteins (LLPs))  
 multiple sclerosis 109  
 systemic lupus erythematosus 111  
 type 1 diabetes 113
- autoimmune myocarditis 168
- autoimmunity 2–3, 159, 161, 169
- autophagy 74, 113, 176, 182–183
- b**
- basal autophagy 182
- Bcl-xL 113
- bone, age-related changes 18
- brain 4
- age-related changes 16
- life span 33
- MALDI IMS 53
- PIMT 16–17
- brown adipocytes 15
- C**
- cardiomyocytes 17, 53, 112, 160
- cardiovascular disease 32, 112
- cartilage 19, 53, 111, 167
- cataract 12  
 age-related 65, 71  
 congenital/early-onset 65, 69  
 and crystallin aggregation 75–77  
 crystallin mutations 68  
 development 60  
 morphologies 68
- cathepsins 176, 181
- celiac disease 166
- cellular polypeptides 1
- central nervous system (CNS) 13, 6,  
 27, 53, 165
- cholangiocytes 20
- chronic inflammatory demyelinating  
 polyneuropathy 165
- citrulline 23, 167  
 codon expansion techniques 146
- collagen 8–10, 26–27, 32, 53, 97, 111, 160
- collisional activation method 180
- collision-induced dissociation (CID) 139
- cornea 12
- covalent crosslinking 9, 29, 101, 102, 161
- Crohn's disease 166
- $\alpha$ A-crystallin 48, 49, 61, 65, 71, 130, 133, 135
- $\alpha$ B-crystallin 48, 61–63, 65, 76–77, 133
- $\gamma$ -crystallin 63–64
- $\gamma$ S crystallin 48, 64, 67–68, 106–107, 128,  
 130, 133, 139, 141, 147, 148
- crystallin bound advanced glycation end  
 products 193
- $\alpha$ -crystallin chaperone action 76, 77
- crystallin mutations 65, 68, 69, 75
- cutaneous aging 8, 9
- $\alpha$ -cyano-2-hydroxycinnamic acid  
 (CHCA) 45

**d**

- deamidation 69
  - insolubilization of crystallins 132–133
  - peptide standards 145
  - site identification 139–142
  - in vitro* studies 135
- dehydroalanine (DHA) 130
- dehydroascorbic acid 190, 191, 195
- dementia 6, 26, 74, 108, 109
- desmosine 7
- desorption electrospray ionization (DESI)
  - IMS 43, 46
- 2,5-dihydroxyacetophenone (DHA) 45
- disulfide bond
  - and age-related cataracts 128–129
  - at individual cysteines in cataractous lens 129
  - in vitro* studies 133–134
- disulfide crosslinks identification 138–139
- disulfide linked cysteines in crystallins 129–130
- DNA damage 21, 22

**e**

- elastin 7–8, 16, 26, 30, 32, 112, 160
- electron capture dissociation (ECD) 142, 180
- electron transfer dissociation (ETD) 47, 139, 142
- endothelial cells 19, 20, 160
- epimerization 178–184
- epithelial cells 11, 48, 60, 160
- equatorial cones 13
- extracellular matrix (ECM), LLPs
  - collagen 8
  - elastin 7–8
  - proteoglycans 8
  - structural glycoproteins 8
- extracellular matrix protein (ECMP) 111–112
- eye
  - cornea 12
  - retina 13–14
  - vitreous humor 12–13
- eye lens 11, 59

- crystallin proteins 61–64
- development 59, 60
- epithelial cells 60
- structure 59, 60

**f**

- familial amyotrophic lateral sclerosis (fALS) 110–111
- fasting 182
- fibrillar collagen 112
- fixed tissue 44
- Fourier transform ion cyclotron resonance (FTICR) 45, 141
- free radical theory of aging 161
- frozen tissue 44, 46

**g**

- glaucoma 14
- glucose vs. ascorbic acid 193–195
- glutathione system 23–24, 163
- Grave's disease 166
- Guillain-Barre syndrome 165
- G18V mutation of  $\gamma$ S-crystallin 69

**h**

- haemodialysis-related amyloidosis 114
- hair 18–19
- hallmarks of aging 6
- Hashimoto's thyroiditis 166
- hearing 21
- heart, age-related changes 17
- hemoglobin 51–53
- higher-energy collision dissociation (HCD) 47, 139
- histones 2, 16, 19, 22, 26, 52, 111, 160
- human  $\alpha$ A-crystallin 48, 76
- human crystallins 61, 131
- hydroxylysine residues 8
- hydroxyproline (hydroxyPro) 8

**i**

- imaging mass spectrometry (IMS)
  - DESI 46
  - fixed tissue 44
  - frozen tissue 44
  - LAESI 46–47

imaging mass spectrometry (IMS) (*Contd.*)

- MALDESI 46
- MALDI 44–45
  - protein identification 47
  - retina 52
- SIMS 46
- inflammaging paradigm 196
- insolubilization of crystallins 128
  - deamidation, isomerization and racemization 132–133
  - disulfide bonding 128–129
  - non-disulfide crosslinking 130
  - non-enzymatic hydrolysis in human lens 131–132
  - protein fragmentation 131
  - proteolysis in animal lens 131
- in-source dissociation 139
- intestine 20, 160
- intracellular LLPs/LLCs, organs and tissues 11
  - adipose tissue 15
  - brain 15–17
  - eye 11–14
  - hair 18–19
  - heart 17
  - intestine 20
  - joints 19
  - kidneys 15
  - liver 20
  - oocytes 14–15
  - pancreas 19, 20
  - skeleton 18
  - teeth 18
- isodesmosine 7
- isoDGR motif 113
- isomerisation 100, 178
  - formation mechanism 178
  - insolubilization of crystallins 133
  - peptide standards 145
  - site identification 142–143

**j**

- joints
  - age-related changes 19
  - rheumatoid arthritis 167

**k**

- kidneys 15

**l**

- laser ablation electrospray ionization (LAESI) 43, 46
- lens
  - cataract 12–13
  - MALDI-IMS images of 48–51
  - presbyopia 12–13
- lenticular ascorbic acid
  - concentrations 190
- life-long protein degradation 31
- lipofuscin 13–14, 113
- L-isoAsp repair 179
- liver, age-related changes 20
- LLCs *see* long-lived cells (LLCs)
- LLPs *see* long-lived proteins (LLPs)
- long-lived cells (LLCs) 160 *see also*
  - intracellular LLPs/LLCs
    - definition 6
    - MIMs-EM 53–54
- long-lived protein decomposition
  - consequences of 163–165
  - oxidation-related modification 163
  - rebuilding degraded Asp and Asn sites 162–163
- long-lived proteins (LLPs) *see also*
  - intracellular LLPs/LLCs
    - age-related disorders 3, 97, 159
    - abundant macromolecules 26
    - autoimmune diseases 25
    - central nervous system 108–109
    - collagen 26
    - cytosol/nuclear communication 25
    - digestive system 112–113
    - elastin 26
    - human eye 106
    - limitation 105
    - mass spectrometry 105
    - nuclear transcription 26
    - treatment of 114
- aging 1, 6
  - in aging and disease
    - animal models 28–29

- heterogeneous 29
  - autoimmunity 2–3, 161
  - brain 4
  - breakdown processes 22–23
  - category 5
  - cellular processing 24
  - consequences 24–25
  - decay in tissue function 32
  - definition of 5
  - degradation and tissue function 30
  - dividing cells 21
  - DNA, aging 28
  - DNA damage 21–22
  - ECM
    - collagen 8
    - elastin 7
    - proteoglycans 8
    - structural glycoproteins 8
  - human lens 3
  - identification 180
  - IMS 43–44
  - intracellular 10–11
  - isomerization and epimerization 176
  - life span
    - brain 33
    - heart 32
    - lung 33
    - nerves 33
  - lipidation events 161
  - mechanistic considerations 181–182
  - memory 4
  - myelin basic protein 31
  - neurological diseases
    - AD 27–28
    - ALS 27
    - MND 27
    - multiple sclerosis 27
  - non-enzymatic modification
    - of 99–100
  - oxidation 23–24, 161
  - PIMT 24
  - protein modification 24
  - protein turnover 180–181
  - repair 179
  - in tissues 160
  - truncation 103
  - lung
    - age-related changes 18
    - lifespan 33
  - lysosomal storage disorders 110, 181
  - lysosome-mediated degradation 175
- m**
- Maillard reaction 189, 191, 197
  - mass spectral imaging 160
  - mass spectrometry (MS)
    - LLP 44–47
    - proteomic characterization by 180
  - matrix-assisted laser desorption electrospray ionization (MALDESI) 43, 46
  - matrix-assisted laser desorption/ionization (MALDI) IMS
    - cartilage 53
    - CNS 53
    - human brain 53
    - lens 48–51
    - molecular weight 45
    - optic nerve 51–52
    - protein types 45
    - spatial resolution in 44
    - workflow for 44–45
  - memory 4
  - metabolism 15, 26, 183
  - methionine sulfoxide
    - reductases 23–24, 163
  - methylation of lens proteins 161
  - MG-H1 formation 195–196
  - $\beta_2$ -microglobulin amorphous aggregates 74, 75
  - molecular chaperones 71–73
  - motor neuron disease (MND) 27, 110–111
  - multi-isotope imaging mass spectroscopy–electron microscopy (MIMs-EM) 53
  - multiple autoimmune syndrome (MAS) 169
  - multiple reaction monitoring (MRM) 146
  - multiple sclerosis (MS) 27, 53, 109, 165–166, 168–169
  - muscle mass 6, 32
  - myasthenia gravis 166

myelin basic protein (MBP) 23, 25, 31, 43,  
51–53, 109, 166, 168  
myelin proteins 16, 109, 166

**n**

nanospray desorption electrospray ionization  
(nano DESI) 46, 53  
negatively impacted proteins 175  
neurological diseases, LLPs  
AD 27–28  
ALS 27  
MND 27  
multiple sclerosis 27  
neuronal SOD1 111  
NGR motif 113  
non-enzymatic crosslinking 101, 102  
nonself-antigens 25  
nuclear transcription 26  
nucleoporin 114

**o**

oocytes 14–15  
optic nerve, MALDI-IMS 51–52  
Orbitrap instruments 45–47, 141  
organs 10–11  
osteoarthritis, pathogenesis 112  
osteoporosis 18  
oxidation (lens protein) 71

**p**

pancreas 19, 20, 165  
parallel reaction monitoring (PRM) 146  
Parkinson's disease (PD) 16, 21, 53, 74, 75,  
110, 196  
pernicious anemia 166  
phosphomimics 71  
phosphorylation 69, 71, 78, 99, 130,  
136–138, 146  
polymorphism, in amyloid fibrils 74  
polymyalgia rheumatica 168  
polymyositis 168  
posterior vitreous detachment (PVD) 13  
post translation modifications (PTMs) 99,  
106, 127  
and aging 103–105

future studies 145–148  
of human lens crystallins  
deamidation 69, 70  
oxidation 71  
phosphorylation 71  
racemisation 70–71  
truncation 71  
identification  
deamidation site 139–142  
disulfide crosslinks 138–139  
isomerization site 142–143  
mass spectrometry 135  
racemization site 143, 145  
searches for known 136–137  
searches for unknown 137–138  
two-dimensional liquid  
chromatography/MS 136  
*in vitro* studies 133–134  
presbyopia 12, 30, 97  
proinsulin 113  
prolylcarboxypeptidase 176  
protein aggregates 3, 30, 61, 71–77,  
128, 130  
protein crosslinking 101, 102  
protein folding, molecular chaperones  
involved in 72  
protein hydrolysis 131  
protein isoaspartate methyl transferase  
(PIMT) 5, 16, 100–101, 162, 177, 179,  
180, 183  
protein lipidation 161  
protein off-folding pathway 72, 73  
protein on-folding pathway 72  
proteins 11, 25, 32, 76, 97, 128, 130, 135,  
136, 146, 148, 168, 176, 178  
protein turnover and metabolic  
activity 180  
proteoglycans 8, 112  
proteolysis, protein insolubilization in animal  
lens 131  
proteostasis 1, 6, 78, 175–176, 180, 183  
psoriasis 167  
PTMs *see* post translation  
modifications (PTMs)  
pulmonary function 33

**q**

Q155X mutant of  $\beta$ B2-crystallin 69

**r**

racemization 30, 70, 100  
 insolubilization of crystallins 132–133  
 peptide standards 145  
 site identification 143–145  
 radical-directed dissociation 143, 180  
 retina  
 age-related changes 13–14  
 age-related deterioration of 108  
 AMD 14  
 glaucoma 14  
 IMS 52  
 pulse-chase experiments 52  
 structure 13  
 retinal detachment 13  
 retinal pigment epithelial (RPE)  
 cells 13–14  
 R120G mutant of  $\alpha$ B-crystallin 69  
 rheumatoid arthritis (RA) 19, 167

**s**

sclera 108  
 scleroderma 167  
 Sclerosing cholangitis 166  
 secondary ion mass spectrometry  
 (SIMS) IMS 46  
 sensory tissues 21  
 SILAM approach 53  
 sinapinic acid (SA) 45  
 single molecule biophysics 115  
 Sjogren's syndrome 167  
 smell 21  
 solid state peptide synthesis (SSPS) 146

spontaneous isomerization of amino  
 acids 178  
 sporadic ALS (sALS) 110, 111  
 stable isotope labelling 7, 27, 46, 53,  
 129, 160  
 steric zippers 74  
 structural glycoproteins 8  
 D-succinimide 99  
 superficial digital flexor tendon (SDFT) 9  
 $\alpha$ -synuclein 74, 76, 110  
 $\alpha$ -synuclein amyloid fibril-forming  
 pathway 77  
 synthetic peptide standards 143, 145  
 systemic lupus erythematosus  
 (SLE) 111, 167

**t**

Tau protein 109–110  
 teeth 18  
 thiol compounds 163  
 time-of-flight (TOF) 45  
 tropoelastin 7, 8  
 truncation 12, 22, 48–51, 70, 71, 78,  
 102–103, 106, 111  
 type 1 diabetes 113, 165  
 type-II diabetes 74

**u**

unfolded protein 72, 74

**v**

valine 7, 69  
 vasculitis 166  
 vitamin C 190, 192  
 vitreous humor 108  
 properties of 12–13  
 retinal detachment 13











